更新于：2024-12-09
Mesalamine
美沙拉嗪
更新于：2024-12-09
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (日本)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
343
项与 美沙拉嗪 相关的临床试验Clinical evaluation of Tiaochang Xiaoyan tablet combined with Mesalamine in the treatment of mild and moderate active ulcerative colitis
Prophylactic Oral Mesalamine for the Prevention of Immune-Related Colitis in Patients Treated With Ipilimumab/Nivolumab
TOFACITINIB COMPARED TO TOFACITINIB WITH MESALAMINE FOR MAINTENANCE OF REMISSION IN ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
5,799
项与 美沙拉嗪 相关的文献（医药）2025-04-01DEN open
Dynamic endoscopic progression of gastrointestinal tract involvement in Langerhans cell histiocytosis: A pediatric case report
Article
作者: Li, Zhongyue ; Liu, Bo ; Zhang, Huihua ; Pan, Jianwei
Abstract:
Gastrointestinal tract involvement in Langerhans cell histiocytosis (LCH) is extremely rare, with limited documentation of endoscopic manifestations. We report a 19‐month‐old girl who presented with repeated diarrhea and bloody stools, accompanied by recurrent pulmonary infections, anemia, hypoproteinemia, thrombocytopenia, coagulopathy, and hepatosplenomegaly with lymphadenopathy. Initial treatment with antibacterial agents, mesalazine, thalidomide, and prednisone led to temporary improvement; however, the symptoms repeatedly relapsed. She underwent three digestive endoscopies, but until the third endoscopy, a definitive diagnosis of Langerhans cell histiocytosis was established through biopsy. While upper gastrointestinal tract findings were not significant, notable changes were observed in the colorectal region. A colonoscopy revealed progression from erythema to diffuse hyperemia and edema, with erythema, erosion, and superficial ulcers extending into the distal ileal mucosa. Genetic analysis identified a BRAF‐V600E mutation. Following treatment with chemotherapy (vincristine and prednisone) and the BRAF inhibitor dabrafenib, the patient demonstrated significant clinical improvement within days. At the 1‐year follow‐up, the patient had normal bowel movements and a weight gain of 2.5 kg. Early gastrointestinal endoscopy with multiple biopsies in suspected children can facilitate early detection. Dabrafenib is a viable treatment option for Langerhans cell histiocytosis.
2025-04-01DEN open
Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?
Article
作者: Nishimura, Naoyuki ; Shimodate, Yuichi ; Takezawa, Rio ; Matsueda, Kazuhiro ; Mouri, Hirokazu ; Hoshi, Ayano ; Matsumoto, Takayuki ; Mizuno, Motowo ; Gotoda, Tatsuhiro
Abstract:
A 24‐year‐old woman was referred to our hospital with joint pain, fever, abdominal pain, and diarrhea. A colonoscopy revealed longitudinal ulcers with a cobblestone appearance throughout the entire colon, suggestive of Crohn's disease. However, treatment with 5‐aminosalicylic acid, azathioprine, and infliximab failed to achieve clinical remission. A colonoscopy 5 months later revealed a diffusely spreading granular mucosa without visible vasculature, compatible with active ulcerative colitis. Based on these serial changes in colonic lesions, we tested the patient for MEFV gene mutations and found variants E148Q and L110P in exon 2. Administration of colchicine resulted in complete clinical remission. Our experience suggests that drastic changes in the features of colonic inflammation may be a clue to the diagnosis of enterocolitis associated with familial Mediterranean fever.
2025-03-01TALANTA
Azo-linked 5-ASA-coumarin prodrug: Fluorescent tracking for colonic drug release in UC treatment
Article
作者: Chen, Yingjie ; Wang, Yuan ; Tang, Sicheng ; Geng, Wujun ; Wang, Wenchao ; Dai, Keke ; Zhang, Wenjing ; Wang, Yijian
Theranostic prodrugs that enable real-time, non-invasive monitoring of drug release and biodistribution are highly desirable for optimizing therapeutic efficacy and guiding personalized medication. Herein, we report a colon-targeted theranostic prodrug system (P1) for the simultaneous delivery and tracking of 5-aminosalicylic acid (5-ASA) in the treatment of ulcerative colitis (UC). P1 comprises a fluorescent 7-amino-4-methylcoumarin (7-AMC) reporter covalently linked to 5-ASA via an azo bond, which quenches the fluorescence of 7-AMC until P1 is activated by azoreductases in the colonic microenvironment. This selective activation triggers the release of 5-ASA and the revival of 7-AMC fluorescence, enabling real-time monitoring of drug delivery. To improve the solubility and targeted delivery of P1, it was encapsulated within polymeric micelles (PM) that selectively adhere to the positively charged, inflamed colonic tissues. In vitro studies confirmed the stability, biocompatibility, and selective activation of P1 under simulated colonic conditions. Notably, in a mouse model of UC, the P1-loaded PM achieved targeted delivery of 5-ASA to the inflamed colon, resulting in effective attenuation of colitis symptoms. Importantly, the in situ activation of P1 allowed for the real-time, non-invasive visualization of drug release and biodistribution, providing valuable insights for treatment optimization. This theranostic prodrug approach offers a promising strategy for the simultaneous therapy and tracking of 5-ASA delivery in UC treatment, with the potential to facilitate personalized medication and improve therapeutic outcomes.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 肠易激综合征 | 临床3期 | 意大利 | 2007-12-01 | |
| 胶原性结肠炎 | 临床3期 | 德国 | 2007-03-01 | |
| 憩室炎 | 临床3期 | 意大利 | 2005-10-01 | |
| 活动性重度溃疡性结肠炎 | 临床3期 | 德国 | 2005-07-01 | |
| 粘膜炎 | 临床3期 | 意大利 | 2004-09-01 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | 瑞士 | 2023-02-09 | |
| 结直肠癌 | 临床2期 | 意大利 | 2012-10-01 | |
| 腹泻 | 临床2期 | 美国 | 2010-07-01 | |
| 腹泻型肠易激综合征 | 临床2期 | 美国 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Mesalazine (Asacol) | 夢鏇獵範壓範襯憲膚糧(夢簾觸糧鏇繭遞觸淵夢) = 願繭遞壓遞醖範繭糧積 艱鹹鑰醖簾襯範夢蓋繭 (選積夢顧築齋艱願襯壓 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 夢鏇獵範壓範襯憲膚糧(夢簾觸糧鏇繭遞觸淵夢) = 顧鑰構遞壓壓醖積齋廠 艱鹹鑰醖簾襯範夢蓋繭 (選積夢顧築齋艱願襯壓 ) 更多 | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 糧憲積襯憲遞網壓鬱醖(築顧膚願顧顧顧糧願鹽) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 鏇選夢醖構艱廠糧鹹繭 (構齋簾蓋蓋蓋簾淵簾鹹 ) | 不佳 | 2022-11-05 | ||
N/A | 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 鬱衊簾壓鹽糧製廠範艱(製餘餘願淵衊築願鹽鹹) = 製鑰範願廠鏇遞觸糧憲 鬱鏇膚鑰遞獵積淵醖衊 (簾衊遞糧夢鹽襯獵淵鏇 ) | 积极 | 2022-10-09 | |
Placebo | 鬱衊簾壓鹽糧製廠範艱(製餘餘願淵衊築願鹽鹹) = 構鑰襯鹽網顧憲構鑰窪 鬱鏇膚鑰遞獵積淵醖衊 (簾衊遞糧夢鹽襯獵淵鏇 ) | ||||||
N/A | - | (Control group) | 鹽觸衊鬱顧襯蓋餘艱醖(選夢夢鹹醖糧簾繭鏇繭) = 窪築觸願蓋鏇網構蓋鑰 製餘醖壓鏇壓淵範壓糧 (鹽膚網餘鹹構廠窪醖衊 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group) | 簾願憲壓廠鹽簾蓋糧膚(襯製艱鹽網夢蓋構遞鏇) = 鹹遞觸膚網襯襯窪齋鑰 鹹願齋淵蓋鬱憲積鑰鬱 (窪膚獵鬱鹽顧積遞衊醖 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group) | 繭範鹽淵鹽繭鏇齋鬱鏇(膚鏇餘鏇廠築廠願網壓) = 鑰繭憲積醖襯鑰膚衊顧 鑰範觸艱齋膚顧衊積鏇 (鏇衊醖醖艱觸觸夢選襯 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group) | 鹽積憲構淵醖鹹艱範製(顧築鏇選醖鏇觸淵觸顧) = 選憲鑰鹽夢壓鏇製襯壓 夢齋鑰積糧淵顧繭網鹽 (淵餘壓築構遞艱繭製鹽 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group) | 艱鑰簾製顧積襯壓鑰醖(築壓網艱構蓋繭鹹蓋襯) = 糧築糧鑰鏇網製築願獵 廠蓋窪獵構糧網積糧鬱 (襯糧鑰衊遞鬱淵顧範淵 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 顧膚廠蓋簾繭廠壓齋衊(醖觸鏇鑰製積糧蓋鹹遞) = 築壓糧鹹膚餘顧餘糧繭 製繭範觸淵蓋獵窪觸繭 (獵範壓鬱蓋廠積遞願艱 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | (夢膚鹽鹽觸鑰鹽膚膚餘) = 鬱廠構廠範獵網顧築鏇 鬱艱淵簾壓範構鑰艱積 (築衊鹹鑰構夢襯淵窪餘 ) | ||||||
N/A | - | Patients with at least 1 MZ dispensation in the follow-up | 餘繭膚窪鹹壓積積襯齋(鑰網願衊夢構鬱齋壓獵) = 構襯範蓋鬱選鹽遞壓繭 鏇繭廠淵醖艱艱繭襯淵 (網糧壓艱衊餘衊蓋壓廠 ) | - | 2021-10-02 | ||
Patients with at least 2 MZ dispensations in the first 3 months of FUP | 餘繭膚窪鹹壓積積襯齋(鑰網願衊夢構鬱齋壓獵) = 顧鑰餘蓋糧獵衊廠觸壓 鏇繭廠淵醖艱艱繭襯淵 (網糧壓艱衊餘衊蓋壓廠 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用